1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
The curious link: statins, cholesterol and stroke |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 3-4
Catherine Andrews,
Preview
|
|
摘要:
In what has been touted as the most important advance in stroke prevention since the introduction of aspirin, HMG CoA reductase inhibitors [statins] are the new hope for this devastating disorder. At the 4th World Stroke Congress [Melbourne, Australia; November 2000], Professor Pierre Amarenco from Hospital Lariboisiere, Paris, France, chaired a thought-provoking, Pfizer-sponsored, satellite symposium entitled'The role of statin therapy in stroke prevention'where the effectiveness of statins for the prevention of stroke was keenly debated. This curious link between cholesterol, statins and stroke was also explored further by several leading researchers in a Bayer-sponsored satellite symposium on stroke prevention in the elderly.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Glutamate: a new target for pain therapy? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
TACTICS unveiled as tirofiban misses TARGET |
|
Inpharma Weekly,
Volume &NA;,
Issue 1271,
2001,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
Researchers have concluded that'the preferred agent for coronary stenting is abciximab',after the glycoprotein (GP) IIb/IIIa receptor antagonist came out on top in the TARGET*study, which compared abciximab and tirofiban in patients undergoing percutaneous coronary interventions (PCI). This is discouraging news for Merck, who sponsored the study which was designed to evaluate whether tirofiban ['Aggrastat'] could be used as an alternative to abciximab ['ReoPro']. On a more positive note for tirofiban, patients with acute coronary syndromes (ACS) receiving the drug had improved outcomes if treated with an early invasive strategy, rather than a conservative one, in the TACTICS**-TIMI 18 trial. The 2 studies were reported at the 73rd Scientific Sessions of the American Heart Association (AHA) [New Orleans, US; November 2000].
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|